Quick Search 
Drugs of the Future
Register or sign in

Drugs Fut 2021, 46(1): 21
ISSN 0377-8282
Copyright 2021 Clarivate
CCC: 0377-8282
DOI: 10.1358/dof.2021.46.1.3220730
Berotralstat. Plasma kallikrein (KLKB1) inhibitor, Treatment of hereditary angioedema attacks
Gras, J.
Hereditary angioedema (HAE) with C1 esterase inhibitor deficiency is a rare, but potentially life-threatening disease, characterized by recurrent self-limiting bouts of edema. Berotralstat (Biocryst Pharmaceuticals), a small molecule, is a potent and specific inhibitor of human plasma kallikrein activity. In a phase II study, a berotralstat oral liquid formulation showed efficacy for the acute treatment of HAE. In phase II and III studies, once-daily oral berotralstat showed efficacy and was well tolerated as a prophylactic agent for HAE attacks. Currently, the long-term safety of berotralstat is being assessed in a phase II/III study, and in an ongoing phase III study for the prevention of attacks in Japanese patients with HAE. Berotralstat has been granted Sakigake designation by the Japanese authorities; orphan drug designation by the U.S., the E.U. and Japan; fast track designation by the U.S.; and Promising Innovative Medicine designation by the U.K. for the prevention and/or treatment of angioedema attacks. In December 2020, the U.S. FDA approved berotralstat for prophylaxis to prevent attacks of HAE in adults and pediatric patients.

Full Text: PDF 

© Clarivate. All rights reserved.
Copyright NoticeTerms of UsePrivacy StatementCookie PolicyManage cookie preferences